Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ovid Therapeutics Inc. - Common Stock (NQ:OVID)

2.480 +0.090 (+3.77%)
Streaming Delayed Price Updated: 11:16 AM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ovid Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
7 Sorry Biotech Stocks Set to Make Investors Sad ↗
Biotech stocks can be extremely challenging because it takes a long time to bring a therapy to market. Here are some biotech stocks to sell. 
Via InvestorPlace
News headline image
eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Evaluating Ovid Therapeutics: Insights From 6 Financial Analysts ↗
 
Via Benzinga
News headline image
Cracking The Code: Understanding Analyst Reviews For Ovid Therapeutics ↗
 
Via Benzinga
News headline image
Recap: Ovid Therapeutics Q4 Earnings ↗
 
Via Benzinga
News headline image
Nasdaq Surges Over 200 Points; Aaron's Shares Jump ↗
 
Via Benzinga
News headline image
Is the Stock Market Closed on Juneteenth 2024? ↗
Investors wondering if the stock market is closed on Juneteenth 2024 have come to the right place as we have an answer to that question! 
Via InvestorPlace
News headline image
ACHR Stock Alert: Archer Aviation Strikes New Deal With Signature Aviation ↗
Archer Aviation stock is down on Monday after the company alerted ACHR investors to a new MOU signed with Signature Aviation. 
Via InvestorPlace
News headline image
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
AAN Stock Alert: The Aaron’s Company Pops 33% on Take-Private Deal ↗
The Aaron's Company stock is up on Monday after it announced a take-private deal that values AAN shares at $10.10 each. 
Via InvestorPlace
News headline image
Why Is Ovid Therapeutics (OVID) Stock Down 69% Today? ↗
Ovid Therapeutics stock is down on Monday with heavy trading of OVID shares after the company reported a failed Phase3 clinical trial. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Rises 1%; Mustang Bio Shares Spike Higher ↗
 
Via Benzinga
News headline image
US Stocks Mixed; Dow Tumbles Over 100 Points ↗
 
Via Benzinga
Topics Stocks
News headline image
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail? ↗
Takeda Pharmaceutical reveals Phase 3 study data for Soticlestat (TAK-935) in treating Dravet and Lennox-Gastaut syndromes. In 2021, Ovid Therapeutics out licensed the drug. 
Via Benzinga
News headline image
Why Nurix Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
3 Sorry Penny Stocks to Sell in May While You Still Can ↗
Steer clear of these three penny stocks to sell that are plagued by financial instability and mounting losses. 
Via InvestorPlace
News headline image
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for May 2024 ↗
Although the concept of penny stocks to buy is extremely risky, these ideas have the advantage of analysts’ positive assessments. 
Via InvestorPlace
News headline image
OVID Stock Earnings: Ovid Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
OVID stock results show that Ovid Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Over $2M Bet On NextNav? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying ↗
The Dow Jones index closed higher by over 400 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
News headline image
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.